Literature DB >> 19947565

[Indications and clinical outcomes of half-ICSI in 99 cases].

Ya-qin Wang1, Jing Yang, Wang-ming Xu.   

Abstract

OBJECTIVE: To determine an optimal insemination technique for patients suspected of high risk of fertilization failure and undergoing assisted reproduction treatment.
METHODS: Ninety-nine couples were treated by conventional in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) in one cycle (half-ICSI) by dividing the sibling oocytes in halves. The clinical and laboratory data were analyzed, and the rates of fertilization, cleavage, good embryos and clinical pregnancy were compared between different fertilization methods.
RESULTS: In the half-ICSI group, the fertilization rate of ICSI (80.5%) was significantly higher than that of IVF (42.9%) (P < 0.01), and so were the rates of complete fertilization failure (21.2%) and low fertilization (16.2%) of IVF than those of ICSI (0 and 3.0%). No significant differences were observed in the rates of cleavage and good-quality embryos between the two groups (P > 0.05).
CONCLUSION: ICSI can help to avoid complete fertilization failure, achieve more high quality embryos for transfer and improve the rate of pregnancy for patients with high risk of fertilization failure.

Entities:  

Mesh:

Year:  2009        PMID: 19947565

Source DB:  PubMed          Journal:  Zhonghua Nan Ke Xue        ISSN: 1009-3591


  2 in total

1.  Early cumulus cell removal could reduce the available embryo rate in human IVF.

Authors:  Duo Wei; Cuilian Zhang; Baoli Yin; Peng Wang; Juanke Xie; Xiaobing Song; Qi Liu; Lin Hu; Yixuan Zhang; Haoying Hao
Journal:  J Assist Reprod Genet       Date:  2011-11-16       Impact factor: 3.412

2.  Intracytoplasmic Sperm Injection May Not Improve Clinical Outcomes Despite Its Positive Effect on Embryo Results: A Retrospective Analysis of 1130 Half-ICSI Treatments.

Authors:  Nan Peng; Shuiying Ma; Cheng Li; Hui Liu; Haibin Zhao; Lian-Jie Li; Qing Li; Mei Li
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-15       Impact factor: 6.055

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.